AQR Capital Management LLC Buys 54,539 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

AQR Capital Management LLC increased its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 153.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 90,013 shares of the company’s stock after buying an additional 54,539 shares during the quarter. AQR Capital Management LLC’s holdings in Takeda Pharmaceutical were worth $1,165,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of TAK. Rise Advisors LLC purchased a new stake in shares of Takeda Pharmaceutical in the first quarter valued at about $26,000. GAMMA Investing LLC increased its stake in Takeda Pharmaceutical by 50.9% in the 1st quarter. GAMMA Investing LLC now owns 2,864 shares of the company’s stock valued at $40,000 after buying an additional 966 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Takeda Pharmaceutical by 38.6% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,082 shares of the company’s stock worth $43,000 after buying an additional 859 shares in the last quarter. Headlands Technologies LLC purchased a new position in shares of Takeda Pharmaceutical in the 2nd quarter worth approximately $59,000. Finally, Blue Trust Inc. grew its holdings in shares of Takeda Pharmaceutical by 74.0% in the second quarter. Blue Trust Inc. now owns 5,480 shares of the company’s stock valued at $76,000 after acquiring an additional 2,330 shares in the last quarter. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Trading Down 0.1 %

NYSE TAK opened at $14.30 on Friday. The stock has a market capitalization of $45.48 billion, a price-to-earnings ratio of 26.97, a PEG ratio of 0.27 and a beta of 0.54. The business’s fifty day moving average is $14.56 and its 200-day moving average is $13.75. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.26 and a quick ratio of 0.74. Takeda Pharmaceutical Company Limited has a one year low of $12.57 and a one year high of $15.39.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Wednesday, July 31st. The company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.19. The business had revenue of $7.75 billion during the quarter. Takeda Pharmaceutical had a return on equity of 10.11% and a net margin of 6.02%. Equities research analysts predict that Takeda Pharmaceutical Company Limited will post 1.58 EPS for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.